Does @entity1534 eradication therapy for peptic XXXX prevent @entity356 ?

@entity1 @entity1066 @entity356 @entity1534
AIM: To investigate the effects of @entity1534 ( @entity1534 ) eradication therapy for treatment of peptic @entity1066 on the incidence of @entity356 . METHODS: A multicenter prospective cohort study was conducted between November 2000 and December 2007 in Yamagata Prefecture, Japan. The study included @entity1 with @entity1534 -positive peptic @entity1066 who decided themselves whether to receive @entity1534 eradication (eradication group) or conventional antacid therapy (non-eradication group). Incidence of @entity356 in the two groups was determined based on the results of annual endoscopy and questionnaire surveys, as well as Yamagata Prefectural Cancer Registry data, and was compared between the two groups and by results of @entity1534 therapy. RESULTS: A total of 4133 @entity1 aged between 13 and 91 years (mean 52.9 years) were registered, and 56 cases of @entity356 were identified over a mean follow-up of 5.6 years. The sex- and age-adjusted incidence ratio of @entity356 in the eradication group, as compared with the non-eradication group, was 0.58 (95% CI: 0.28-1.19) and ratios by follow-up period (< 1 year, 1-3 years, > 3 years) were 1.16 (0.27-5.00), 0.50 (0.17-1.49), and 0.34 (0.09-1.28), respectively. Longer follow-up tended to be associated with better prevention of @entity356 , although not to a significant extent. No significant difference in incidence of @entity356 was observed between @entity1 with successful eradication therapy (32/2451 @entity1 , 1.31%) and those with treatment failure (11/639 @entity1 , 1.72%). Among @entity1 with duodenal @entity1066 , which is known to be more prevalent in younger individuals, the incidence of @entity356 was significantly less in those with successful eradication therapy (2/845 @entity1 , 0.24%) than in those with treatment failure (3/216 @entity1 , 1.39%). CONCLUSION: @entity1534 eradication therapy for peptic @entity1066 @entity1 with a mean age of 52.9 years at registration did not significantly decrease the incidence of @entity356 .
